HBK Investments’s Apellis Pharmaceuticals APLS Stock Holding History

HBK Investments’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,550,000	Closed	-$143M	–	294
2026 Q1	$143M	Buy	+3,550,000	New	+$76.5M	1.45%	20
2019 Q4	–	Sell	-14,038	Closed	-$338K	–	663
2019 Q3	$338K	Buy	+14,038	New	+$386K	﹤0.01%	569
2019 Q1	–	Sell	-22,058	Closed	-$291K	–	1047
2018 Q4	$291K	Buy	+22,058	New	+$338K	﹤0.01%	1046

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HBK Investments's APLS Position: Q2 2026 in Review

HBK Investments sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 3,550,000 shares — an estimated $143M sold.

HBK Investments first reported a position in APLS in Q4 2018 and held it in 3 quarters. The position peaked at $143M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

HBK Investments reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HBK Investments sold 3,550,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $143M.
HBK Investments first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 3 quarters.
HBK Investments's Apellis Pharmaceuticals position peaked at $143M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on HBK Investments's 13F filing for Q2 2026, filed 14 Aug 2026.